Banner News

Singapore, March 22, 2022 - Credo Diagnostics Biomedical Pte Ltd is pleased to announce the celebration of its 11th anniversary and official move into a new office at #06-01 Valley Point, Singapore.


“Since our incorporation on 22nd March 2011, we have grown and weathered many storms. COVID-19 was a game-changing moment as we were given a chance to participate in the fight against the pandemic. Our VitaPCR™ Instrument and COVID-19 related assays are now used in many parts of the world – from mobile drive-through testing stations to major airports, cruise ships, laboratories, oil drilling platforms, and even onboard the frigates of a major European Navy fleet. The Credo solution is easily associated by many users as the solution for quick and accurate point-of-care molecular tests” said Dr. Wong Jr. Winston, Chairman, and CEO of Credo Diagnostics Biomedical.


“Today, it is a great honour to see our solution accepted and requested by users around the world. We strive to continually provide the best solutions to our customers and will never stop innovating.” continued Dr. Wong Jr. Winston.


To mark our 11th anniversary, Credo Diagnostics Biomedical will embark on the next phase of growth – by launching our next range of assays and continuing our mission “Affordable Advanced Medical Technology for All.”


About Credo Diagnostics Biomedical Pte. Ltd.

Credo Diagnostics Biomedical develops and manufactures innovative, easy-to-use, and rapid molecular diagnostic solutions for Point-of-Care (POC) applications at affordable costs without compromising accuracy and speed in the areas of Human Health. Leveraging solid and established science, combined with efficient integration and strategic innovation, Credo Diagnostics Biomedical provides advanced medical technologies for all.


We at Credo Diagnostics pioneer accessible diagnostic platforms to improve the lives of those we love. We believe providing the right information to the right people at the right time leads to better outcomes.